ProHeart 6 (moxidectin): The Value of the Second Dose
ProHeart? 6 (moxidectin): The Value of the Second Dose*
Introduction
ProHeart 6, an injectable prescription parasiticide, is the only U.S. Food and Drug Administration (FDA)-approved injectable heartworm disease preventative that protects dogs for six months against heartworm disease caused by Dirofilaria immitis; it also treats preexisting infections with common hookworms (Ancylostoma caninum and Uncinaria stenocephala).
ProHeart 6 is the only heartworm disease preventative that ensures six months of continuous protection in a single dose and can only be administered by veterinarians and staff.
A 2015 study analyzed a total of 1,626 veterinary invoices for 918 dogs receiving an appropriately timed second dose of ProHeart 6 (within 5?7 months of an initial dose). The study found that beyond ensuring year-round compliance with a heartworm disease prevention regimen, the second dose offers additional benefits for the patient, the pet owner and the practice (Figure 1).
Figure 1 -- Benefits of the ProHeart 6 Second Dose
For the Patient Year-round protection Early detection of disease
For the Pet Owner Convenient peace of mind
For the Veterinary Practice Veterinarian-controlled compliance Healthier practice
About the study
This study enrolled 18 veterinary practices from eight states. All practices supplied invoices for 2009?2014. The 1,626 invoices analyzed in the study all met the criteria for a ProHeart 6 second dose (i.e., one given 5?7 months after the initial dose). The invoices also included anonymous data about health observations, patient health status, medical issues addressed, products or services the client purchased during the visit and any charges associated with the visit. All patients met the label requirements for ProHeart 6 administration; no exclusion criteria were applied for patient age, breed, size or gender.
TABTLAEB1L:EM1:EMDTIECADABILCLAEISL1S:IUSMESESUDEIIDSCEAINDLTEIINSFSITEUIDFEIESADTIDAPETRNOPTHRIFEOIAHERDETAAR6TTP6ROHEART 6
Key findings
SECSOENCODNVDISVITISS*EITC*OND VISIT* DiaDginaogsnisosTiyspTeDyipaegnosis Type
TABLE 1: MEDICAL ISSUES IDENTIFIED AT PROHEART 6 PerPcerncteangtea(gNePSo(eE.N)rCcoSTOe.AE)STNnBCAEtDOLaBCEgNVOLe1EIDNS:(1DNIVMT:IoVM*SE.I)DSETIDI*CTIA*CLAILSISSUSEUSESIDIEDNETNITFIEFIDEDATAPTRPORHOEHAERATR6T 6
Medical issues addressed DermDaetromloagtoiclogic Dermatologic
28.32%8.3%(100(/13D05i03a2/)38gD5.n33iD%a)oigsanigson(Ts1o0yis0p/ie3Ts5y3Tp)yepe
Percentage (No.) PePrecrecnetnatgaeg(eN(oN.)o.)
As a direct consequence of being broDuengDtahel nttalin forDpenhtayl sical exams at the time of the ProHeart 6 seconOdticOdtioc se, 21O.7tic% of patients
ElecEtilveectsivuergseurrygeErlyective surgery
18.71%8.7% (66/3D(65e63r1/)m385.a73to%)logic (66/353) DeDrmeramtoaltoogloicgic
12.21%2.2% (43/3D(45e33n1/)3t2a5.l23%) (43/353) 10.81%0.8% (38/(3O358t3i1/c)30D5.8e3D%n)teanltal (38/353)
28.3% (100/353) 282.38%.3% (10(100/305/35) 3)
18.7% (66/353) 181.78%.7% (66(6/365/35) 3)
12.2% (43/353)
(353/1,626) had at least one medicOartlhOoisprtehsdouipceedicadOdrrtheospesdeicd at the
8.8%8.8% (31/3E(35l1e3/c)38Ot5i.8vt3Oi%ec)tiscurge(r3y1/353)
121.22%.2% (43(4/335/35) 3) 10.8% (38/353)
time of the second dose. Of those 35U3rogUpernoaigttaelineitanl ts,U3ro1g5enit(a8l 9%) had
3.4%3.4% (12/3O(15r23th/)33oE5.p4l3eeE%)dclitecicvteivs(eu1rs2gu/3er5gry3e)ry
101.80%.8% (38(3/385/335)3) 8.8% (31/353)
a new medical condition diagnosed. GTahstGreoaisnnttreoesitnwitneasltyinaGildasetrnoitntiefsiteindal issues
3.1%3.1% (11/3U(15r13o/)g33Oe5.n1r3Oti%)htarotlhpoedpie(cd1i1c/353)
8.88%.8% (31(3/315/35) 3) 3.4% (12/353)
spanned a wide range of acute, chroOnphiOtchpahlamthniacldmicothOpehrthaclmoinc ditions. Table 1 shows the breakdown of medMicetaaMbleotliaiscbosluices Mideteabnolticified at the time of the ProHeart 6 second-doseCvairsdCiioatlro.dgioiclogic Cardiologic
All oAthlleor ther All other
UrUogroengietnailtal 3.1%3.1% (11/3G(15a13s/)t33r5o.13in%)testina(l11/353) 2.5%2.5% (9/3O5(p93h/)3t2Gh5.a5a3Gl%s)mtarisoctirnotienst(tei9ns/ta3iln5a3l) 2.3%2.3% (8/3M5(8e3t/)a32Ob5.3op3O%lh)iptchhatlhmalimc(8ic/353) 6.8%6.8% (24/3C(25a43r/d)36Mi5o.83leMo%)tagebitcoablioc(li2c4/353)
3.43%.4% (12(1/325/35) 3) 3.1% (11/353)
3.13%.1% (11(1/315/35) 3) 3.1% (11/353)
3.13%.1% (11(1/315/35) 3) 2.5% (9/353)
2.52%.5% (9/(395/35) 3) 2.3% (8/353)
MedMiceadl icssaul eissauses%Masoefd%itcooatafllitsocstauasleescsaasse%s of total cases21.72%1.7%(353(/315,A632/l1l62,o)61Ct2.h7a6eCr%)rdairodl(io3og5loi3cg/1ic,626)
2.32%.3% (8/(385/35) 3) 6.8% (24/353)
AlAl ollthoetrher NewNmewedmicaelddicialgdnioNasgeewnsoamssee%sdaisocaf%ltodotiafalgtocnatoassleecssaasess% of tot1a9l.c4a1%s9e.s4%(315(/311,M652/e161d,)69ic2.4a6l%)issu(3es15a/s1%,62o6f)total cases
6.86%.8% (24(2/345/35) 3) 21.7% (353/1,626)
MeMdiecdailciaslsiusessueas a%s %of otofttaoltcaal sceasses
212.71%.7%(35(35/13,/612,62) 6)
New medical diagnoses as % of total cases
19.4% (315/1,626)
*Prio*rPPriroorHPeraorHt 6eadrot s6*ePdgroiovser nPgrivoneHpnereianvrtipo6ruedsvoi5so-eu7sgmi5vo-e7nntmhinso.nptrhesv.ious 5-7 months.
NeNwemwemdiecdailcdailadginaogsneosseas a%s %of otofttaoltcaalsceasses
191.49%.4%(31(351/15,/612,62) 6)
*Prior ProHeart 6 dose given in previous 5-7 months. *Pr*iPoriPoroPHroeHareta6rtd6osdeogseivgeinvein pinrepvrieovuisou5s-75m-7omntohnst.hs.
Additional services and
TABTLAEB2L:EA2D: DAIDTTADIOBITNLIEOAN2L:ASALEDRSDVEIITRCIVEOISNCEOASBLTOSABEIRTNAVEIDNCESDOBTAINED TABTLAEB3L:EA3D: DAIDTTADIOBITNLIEOAN3L:APALRDOPDDRITUOICDOTUNSCATOLSBPTORABOITNDAUEIDNCTESDOBTAINED
products obtained
BYBCYLICENLITESNTASBT YAPTRCOLPIHREEONAHTRESTAAR6TTSPE6RCSOOEHNCEODANRVDTISV6ITISSEITCONDTAVBISLEIT2: BAYDBDCYILTICIEONLNITEASNLTASSBTEYAPRTRCVOLPICIHREEEONSAHTORESTBAATR6TATSPIEN6RCESOODEHNCEODANRVDTISV6ITISSEITCONDTAVBISLEIT3:
The ProHeart 6 second-dose visit alsoSesraSvweicrevi1ce1
ServiceI1NnvooI.Nni(cv%ooe.)is(c%e)s
MNoeM.a(n%ea)n CInhvaCorhgicaeergse
78.9% of clients (1,283/1,626) obtaining
VaccVinacactiionnastions Vaccination3s79 3(7293)(23) $33769.$3(3263.)33
other products, services or both. Tables 2 HearHtweaorrtmwotermstitnegsHtinegartworm2t9e7st2i(n91g78)(18) $22997.$0(2198.)01
CM$BSh3aeeY6rr.a3gCvTBSn3iAeLeYcTBSIBrAeEeYCvL1NBriLEcCvPPILTieEeLr2EcSt1IoN:eEsPP2duAAT1Ne:rputTSDopATscldDuPiSDAtepuRIsTDpTAclOiIPtTeTOHsRIPNIEOONnRAAPPNvHoOeRroLAIt.EoHNnTis(SALcdu%IvEoNn6pEeuRoSA.p)vRscoSTilE(RociV%t.eER6Ties(IcCV%)CsS6eOIE)ECsSNSCICE1MnENDhO7SOvC5aoeNoIBVOCO1nr.a(MNig71IDThNc(vBnCS51%oAeMaoee)DThIV.(rIiaTs)A1aeNcg(I1Vn1%SrIaee)ENgInsS)TDeE1ITDCI1MnNh$7v25aoeoC3Mr.a(.ih$71gc(n271a%eee3)ra.s)7gn17eBPrYoCdTBPCMAuLrYh$TBPoIc2BaeAErY3CdtroLa.NBuL7gECdn
$V2a9c.c0i1nationsFleaFcloenatcrolntrol 3F7l9ea(2c3o)ntrol 1$43061.34(309) (9) 1$4307.$6(3697).66 Pet sup$p3li7e.s6
and 3 show these additional servicesFeacanFletdceastlitnegsting Fecal testin2g75 2(7157)(17) $23725.$3(31527.)35
VaVccaicncaitniaotnios ns
37397(923(2) 3)
$3$63.363.33
PePt seut psup
$H3e2a.r3t5worm tFelsetainF/tgliecak/tciockntcrolnt2roF9ll7ea(/1t8ic)k control 1$32591.03(158) (8) 1$358.$5(5988).59 Flea co$n5tr8o.5l
products, as well as the mean chargBeloofBdolowroodrkwork Blood work101 10(16) (6)
each item. Vaccinations were the mBooarBsdoitnagrding Boarding 86 8(65) (5) common additional services (23.3%NailoNtrafiiml trim Nail trim 81 8(15) (5) invoices, mean charge $36.33), andSurpgSeeuryrtgery Surgery 64 6(4) (4)
AnaAl snaacl esxapcreexspsiroenAssnioanl sac exp5r6ess5i(o63n) (3)
supplies were the most common additAinoenAsthnaelsitahesia Anesthesia 53 5(3) (3)
$18031.$187(36.)17 $9806.$490(05.)40 $1821.$217(25.)27 $1648$.116(48).11 $1546.$412(43.)42 $583.$051(83.)01
$F8e3c.a1Hl7teeHasrteitanwrgtoAwrnmotriAmtbeinsotttetiiibnsctigsiontgics 2A75nt(2i1b97i27o)9t(i71cs8(1) 8) 1$23121.3$2(5217$9) 2.0(971.)01
$B9lo0o.4Fd0ewFcaeolcrktaelAsttelilnsetgAringlgyletrrgeyattmreeantmt1eA0n1ltle2r(7g625y)7(t5r1e7(a1)tm7)ent$7843.1$7(7345$2) 3.3(255.)35
$B1o2a.r2Bd7ilnoBgolodowdNowSrkAoNrIkDSAs IDs
N86SA1(0I5D1)0s1(6)(6) $7940.4$7(0845$3) 8.1(357.)17
$N16a8il.1Bt1roiBmarodairndDginiegtDariyetary
D81ieta(8r56y)86(5)(5) $7102.2$7(7904$0) 9.4(040.)40
NaNilatirlimtrim
8181(5)(5)
$1$21.227.27
$S1u4rg.4e2ry IntesItnitneasltipnaarlapsiatriacsiI6dint4eitcseisd(ti4ens)al parasiti$c12id65e8s.12(152) (2)
$A5n8a.l0Ss1uaSrcgueerxrgypeMrreyesdsMioceandtiiocnatrieofnilrlsefMi5l6lsedi(6c34a)6ti4o(n4)(r4ef)ills$2124$.421(221$6)186.(1811.)11
1$2319.$2(3079).20 Flea/Ftilce$Fka3le9ccao.o2nnc $7344.$1(3854).18 AntibFiloe$Fta3il/ce4tsai.c1/tk $7343.$7(3653).76 AllerAgyn$At3tirnb3eti.aio7btt $7301.$4(3641).46 NSAAIDl$Alse3lr1lge.y4rg
NSNASIADIs $2151.$9(1021).90 Dietary$11.9 $229.$9(2719).97 IntesDtini$Dea2tlia9epr.ty9aar
products (10.8% of invoices, mean chEaarrtEgreaearttmreeantmt ent Ear treatmen3t9 3(92) (2) $2359.$329(52.)39
$A2n5e.s3At9hneAaslniasaalScsahecaxmpSexrhpepaosrmoseisposonioon S5h3am(53p6)o5o6(3)(3) $1538(.0 ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- merck rebate program extraordinary savings for
- medication formulation quantity price quantity price
- material safety data sheet msd animal health
- buy 2 doses of bravecto save 15 rebates coupons
- bravecto chewables for dogs canadapetcare
- proheart 6 moxidectin the value of the second dose
- caution mode of action description dosage bravecto
- client information sheet flea and worm treatments
- heartland veterinary supply pharmacy prescription policy
Related searches
- compute the value of the correlation coefficient
- find the value of the interquartile range
- calculate the value of the sample variance
- find the value of the variable calculator
- calculate the value of the determinant
- examples of the second law of motion
- history of the second amendment
- interpretations of the second amendment
- definition of the second amendment
- benefits of the second amendment
- compute the value of the test statistic
- determine the frequency of the second class